Nothing Special   »   [go: up one dir, main page]

WO2001010406A3 - Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow - Google Patents

Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow Download PDF

Info

Publication number
WO2001010406A3
WO2001010406A3 PCT/US2000/021929 US0021929W WO0110406A3 WO 2001010406 A3 WO2001010406 A3 WO 2001010406A3 US 0021929 W US0021929 W US 0021929W WO 0110406 A3 WO0110406 A3 WO 0110406A3
Authority
WO
WIPO (PCT)
Prior art keywords
blood flow
optic nerve
choroidal
sight
preservation
Prior art date
Application number
PCT/US2000/021929
Other languages
French (fr)
Other versions
WO2001010406A2 (en
Inventor
William E Sponsel
Original Assignee
Univ Texas
William E Sponsel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, William E Sponsel filed Critical Univ Texas
Priority to CA002378257A priority Critical patent/CA2378257A1/en
Priority to AU65365/00A priority patent/AU779991B2/en
Priority to EP00952721A priority patent/EP1246605A2/en
Priority to JP2001514927A priority patent/JP2003506394A/en
Publication of WO2001010406A2 publication Critical patent/WO2001010406A2/en
Publication of WO2001010406A3 publication Critical patent/WO2001010406A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method for improving visual function and maximizing the health of the optic nerve and retina by increasing blood flow velocity therein through the application of an effective amount of a formulation of an agent that increases levels of cyclic-GMP, increases levels of nitric oxide or inhibits phosphodiesterase.
PCT/US2000/021929 1999-08-10 2000-08-10 Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow WO2001010406A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002378257A CA2378257A1 (en) 1999-08-10 2000-08-10 Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
AU65365/00A AU779991B2 (en) 1999-08-10 2000-08-10 Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
EP00952721A EP1246605A2 (en) 1999-08-10 2000-08-10 Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow
JP2001514927A JP2003506394A (en) 1999-08-10 2000-08-10 Method for increasing optic nerve, choroid and retinal blood flow to facilitate retention of vision

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14815099P 1999-08-10 1999-08-10
US60/148,150 1999-08-10

Publications (2)

Publication Number Publication Date
WO2001010406A2 WO2001010406A2 (en) 2001-02-15
WO2001010406A3 true WO2001010406A3 (en) 2002-08-08

Family

ID=22524518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/021929 WO2001010406A2 (en) 1999-08-10 2000-08-10 Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow

Country Status (5)

Country Link
EP (1) EP1246605A2 (en)
JP (1) JP2003506394A (en)
AU (1) AU779991B2 (en)
CA (1) CA2378257A1 (en)
WO (1) WO2001010406A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
SE0202365D0 (en) 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
EP1689397A4 (en) * 2003-11-20 2007-06-20 Othera Pharmaceuticals Inc Amelioration of macular degeneration and other ophthalmic diseases
US20090214624A1 (en) * 2004-11-29 2009-08-27 The University Of Akron Topical nitric oxide donor devices and methods for their therapeutic use
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
WO2006125123A2 (en) 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
JP5162859B2 (en) * 2005-08-31 2013-03-13 大正製薬株式会社 Prevention or alleviation of eye strain
US20120237617A1 (en) * 2009-06-18 2012-09-20 Theravasc Inc. Use of nitrite salts in treating tissue damage
JP5791064B2 (en) * 2009-07-17 2015-10-07 エア・ウォーター株式会社 Pharmaceutical composition
WO2013188217A1 (en) 2012-06-11 2013-12-19 Macuclear, Inc. Therapeutic formulation and methods of treatment
FR3008618A1 (en) * 2013-07-19 2015-01-23 Univ Paris Curie USE OF COMPOUNDS TO RESTORE THE RESPONSE IN THE LIGHT OF CELLS OF THE RETINA
AU2016212527B2 (en) * 2015-01-28 2019-03-07 Realinn Life Science Limited Compounds for enhancing PPARgamma expression and nuclear translocation and therapeutic use thereof
WO2017219080A1 (en) * 2016-06-21 2017-12-28 The University Of Newcastle Treatment for myopia
EP3949958A1 (en) * 2020-08-04 2022-02-09 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound for the treatment and prophylaxis of a lipofuscin-associated disease
EP4154888A1 (en) * 2021-09-24 2023-03-29 Charité - Universitätsmedizin Berlin Pde5 inhibitor for use in the treatment of medical conditions associated with mitochondrial complex v deficiency
CN114177182A (en) * 2021-12-25 2022-03-15 三维医疗科技有限公司 Application of sildenafil citrate/tadalafil/vardenafil in preparation of medicine for treating myopia
EP4233867A1 (en) * 2022-02-24 2023-08-30 Nicox SA Pde5 inhibitor for use in the treatment of anterior ischemic optic neuropathy
WO2024200678A1 (en) 2023-03-28 2024-10-03 Charité - Universitätsmedizin Berlin Pde5 inhibitor for use in the treatment of medical conditions associated with mitochondrial complex iv deficiency

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733745A (en) * 1993-07-19 1995-02-03 Taiho Yakuhin Kogyo Kk 2-nitroimidazole compounds
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
WO1998037894A1 (en) * 1997-02-28 1998-09-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733745A (en) * 1993-07-19 1995-02-03 Taiho Yakuhin Kogyo Kk 2-nitroimidazole compounds
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
WO1998037894A1 (en) * 1997-02-28 1998-09-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRUECKNER: "Therapie der Duchblutungsstörungen des Auges", OESTERREICHISCHE AERZTEZEITUNG, vol. 22, no. 25, 1978, pages 1221 - 1236, XP001038402 *
DATABASE WPI Section Ch Week 199515, Derwent World Patents Index; Class B03, AN 1995-110612, XP002185788 *
SHPAK ET AL: "comparative effectivity of local usage of sodium nitrite, plathyphyllin and complamin in treatment of optic nerve atrophy", OFTALMOLOGICHESKII ZHURNAL, vol. 39, no. 5, 1984, pages 294 - 297, XP001037484 *
ZURAKOWSKI ET AL: "nitrate therapy may retard glaucomatous optic neuropathy", VISION RESEARCH, vol. 38, 1998, pages 1489 - 1494, XP001038084 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US9387224B2 (en) 2003-07-09 2016-07-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of specific cardiovascular conditions with nitrite

Also Published As

Publication number Publication date
EP1246605A2 (en) 2002-10-09
WO2001010406A2 (en) 2001-02-15
JP2003506394A (en) 2003-02-18
CA2378257A1 (en) 2001-02-15
AU779991B2 (en) 2005-02-24
AU6536500A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
WO2001010406A3 (en) Facilitating the preservation of sight by increasing optic nerve, choroidal and retinal blood flow
CA2433849A1 (en) Glaucoma treatment device and method
CA2248087A1 (en) Improved vision through photodynamic therapy of the eye
IL169287A (en) Sterile ophthalmic formulation, an ocular insert for delivery of same and the use of the formulation
EP1378247A8 (en) Visual function disorder improving agents
WO2003039359A3 (en) Accommodating pupil non-concentricity in eyetracker systems
WO2002036162A3 (en) Compositions for treatment of ocular neovascularization and neural injury
WO2006055526A3 (en) Compositions useful to treat ocular neovascular diseases and macular degeneration
CA2361834A1 (en) Offset ablation profiles for treatment of irregular astigmatism
WO2004028570A3 (en) A method for treating severe tinnitus
WO1999063977A3 (en) Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone, triazolam and brotizolam for treating or preventing sleep disorders
WO2000035475A3 (en) Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
WO2002053106A3 (en) Autoantigen composition
EP0879601A3 (en) Ophthalmic drug delivery system
EP2279742A3 (en) Combinations for the treatment of immunoinflammatory disorders
WO2005047938A3 (en) Calibration of a mearement device
AU2002307430A1 (en) Method and system for photodisruption of tissue of the eye
HK1078776A1 (en) Vitreoretinal tamponades based on fluorosilicone fluids
AU4128901A (en) Colored visco-elastic composition
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
WO2000018387A3 (en) Antibiotic compositions for treatment of the eye, ear and nose
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
EP1383529A4 (en) Methods of treating disorders of the eye and surrounding tissue with thymosin 4 (t 4), analogues, isoforms and other derivatives
IS4611A (en) Method to increase blood flow through the cornea and optic nerve to maintain vision

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 65365/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2378257

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000952721

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000952721

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 65365/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000952721

Country of ref document: EP